Drug Trial Radar · NCT05050318
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Sep 8, 2021
Primary completion
Nov 10, 2021
Study completion Nov 10, 2021
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (\<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (\>=) 65 years of age who received Fluzone High-Dose Quadrivalent vaccine for submission to CBER to aid in the influenza vaccine strain selection process.
Conditions
- Influenza Immunization
- Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulationBiological
Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulationBiological
Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2Time frame: Visit 1 (Day 1; pre-vaccination) and 28 days post-final vaccination at Visit 2 (for participants with 1 vaccination)/Visit 3 (for participants with 2 vaccination)
- Number of Participants Aged >=65 Years Who Provided Serum Samples for Analysis: Group 3Time frame: Visit 1 (Day 1; pre-vaccination) and 21 days post-vaccination (Visit 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number :8400001
Bardstown, Kentucky
Investigational Site Number :8400002
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.